RRC ID 6574
著者 Sato K, Koyama T, Shichiri M.
タイトル Biosynthesis and secretion of salusin-alpha from human cells.
ジャーナル Peptides
Abstract Salusins originally identified using bioinformatics analyses have been shown to act on the cardiovascular and endocrine systems. Although the hypotensive activity of salusin-alpha is limited, it exerts a significant anti-atherosclerotic effect via suppression of foam cell formation in human monocyte-derived macrophages by down-regulating acyl-CoA:cholesterol acyltransferase-1. Furthermore, serum salusin-alpha levels show a close negative correlation with the severity of atherosclerotic diseases. However, biosynthesis and secretion of salusin-alpha peptide from cultured mammalian cells have not been demonstrated to date. We examined the expression, synthesis and release of salusin-alpha in human-derived cell lines. Preprosalusin mRNA and protein were detected ubiquitously in all cells tested, whereas the processing of preprosalusin into salusin-alpha peptide is dependent upon each cell type. Immunohistochemical study revealed the most abundant salusin-alpha-like immunoreactivity to be present in HeLa cells which released salusin-alpha-like immunoreactivity into the culture supernatant. Analysis of extracted conditioned media from HeLa cells by reverse-phase high performance liquid chromatography coupled with radioimmunoassay detection revealed a single immunoreactive component that co-eluted with authentic salusin-alpha. These results present the first evidence that salusin-alpha is biosynthesized and released from human-derived cells.
巻・号 29(12)
ページ 2203-7
公開日 2008-12-1
DOI 10.1016/j.peptides.2008.08.015
PII S0196-9781(08)00360-4
PMID 18804130
MeSH Base Sequence Cell Line Humans Intercellular Signaling Peptides and Proteins / biosynthesis* Intercellular Signaling Peptides and Proteins / metabolism Molecular Sequence Data RNA, Messenger / metabolism*
IF 2.843
引用数 14
WOS 分野 PHARMACOLOGY & PHARMACY ENDOCRINOLOGY & METABOLISM BIOCHEMISTRY & MOLECULAR BIOLOGY
リソース情報
ヒト・動物細胞 MKN1(RCB1003)